Access the full text.
Sign up today, get DeepDyve free for 14 days.
B. Evert, M. Eichelbaum, H. Haubruck, U. Zanger (1997)
Functional properties of CYP2D6 1 (wild-type) and CYP2D6 7 (His324Pro) expressed by recombinant baculovirus in insect cellsNaunyn-Schmiedeberg's Archives of Pharmacology, 355
Takeo DeguchiS (1992)
Sequences and expression of alleles of polymorphic arylamine N-acetyltransferase of human liver.The Journal of biological chemistry, 267 25
A. Daly, J. Brockmöller, F. Broly, M. Eichelbaum, W. Evans, F. Gonzalez, J. Huang, J. Idle, M. Ingelman-Sundberg, T. Ishizaki, É. Jacqz-Aigrain, U. Meyer, D. Nebert, V. Steen, C. Wolf, U. Zanger (1996)
Nomenclature for human CYP2D6 alleles.Pharmacogenetics, 6 3
G. Wilkinson, F. Guengerich, R. Branch (1989)
Genetic polymorphism of S-mephenytoin hydroxylation.Pharmacology & therapeutics, 43 1
U. Meyer (1994)
Pharmacogenetics: the slow, the rapid, and the ultrarapid.Proceedings of the National Academy of Sciences of the United States of America, 91 6
M. Blum, A. Demierre, D. Grant, M. Heim, U. Meyer (1991)
Molecular mechanism of slow acetylation of drugs and carcinogens in humans.Proceedings of the National Academy of Sciences of the United States of America, 88
(1994)
Commentary. Pharma P1: SDA/MKV P2: SDA/VKS QC
A. Risch, D. Wallace, S. Bathers, E. Sim (1995)
Slow N-acetylation genotype is a susceptibility factor in occupational and smoking related bladder cancer.Human molecular genetics, 4 2
W. Weber, D. Hein (1985)
N-acetylation pharmacogenetics.Pharmacological reviews, 37 1
S. Sindrup, Kim Brøsen (1995)
The pharmacogenetics of codeine hypoalgesia.Pharmacogenetics, 5 6
L. Estabrooks, K. Rao, D. Driscoll, B. Crandall, J. Dean, E. Ikonen, B. Korf, A. Aylsworth (1995)
Preliminary phenotypic map of chromosome 4p16 based on 4p deletions.American journal of medical genetics, 57 4
D. Evans, P. Krahn, N. Narayanan (1995)
The mephenytoin (cytochrome P450 2C 19) and dextromethorphan (cytochrome P450 2D6) polymorphisms in Saudi Arabians and Filipinos.Pharmacogenetics, 5 2
C. Martı́nez, J. Agúndez, M. Olivera, R. Martin, J. Ladero, J. Benítez (1995)
Lung cancer and mutations at the polymorphic NAT2 gene locus.Pharmacogenetics, 5 4
Masahiko Watanabe, T. Sofuni, T. Nohmi (1992)
Involvement of Cys69 residue in the catalytic mechanism of N-hydroxyarylamine O-acetyltransferase of Salmonella typhimurium. Sequence similarity at the amino acid level suggests a common catalytic mechanism of acetyltransferase for S. typhimurium and higher organisms.The Journal of biological chemistry, 267 12
(1992)
Detection of a new polymorphism of human arylamine N-acetyltransferase NAT1 using p-aminosalicylic acid as an in vivo probe
Richa Saxena, Gall Shaw, M. Relling, James Frame, Donald Moir, William Evans, Neil Caporaso, Barbara Weiffenbach (1994)
Identification of a new variant CYP2D6 allele with a single base deletion in exon 3 and its association with the poor metabolizer phenotype.Human molecular genetics, 3 6
Alison Ward, M. Summers, Edith Sim (1995)
Purification of recombinant human N-acetyltransferase type 1 (NAT1) expressed in E. coli and characterization of its potential role in folate metabolism.Biochemical pharmacology, 49 12
W. Kalow (1980)
Pharmacogenetics of drug metabolismTrends in Pharmacological Sciences, 1
K. Weerasuriya, R. Jayakody, C. Smith, C. Wolf, G. Tucker, M. Lennard (1994)
Debrisoquine and mephenytoin oxidation in Sinhalese: a population study.British journal of clinical pharmacology, 38 5
R. Minchin (1995)
Acetylation of p-aminobenzoylglutamate, a folic acid catabolite, by recombinant human arylamine N-acetyltransferase and U937 cells.The Biochemical journal, 307 ( Pt 1)
(1953)
Enzymatic inactivation of isonicotinic acid hydrazide in humans and animals
D. May, C. Black, N. Olsen, M. Csuka, S. Tanner, Lisa Bellino, James Porter, G. Wilkinson, R. Branch (1990)
Scleroderma is associated with differences in individual routes of drug metabolism: A study with dapsone, debrisoquin, and mephenytoinClinical Pharmacology & Therapeutics, 48
L. Jorge, T. Arias, U. Griese, D. Nebert, M. Eichelbaum (1993)
Evolutionary pharmacogenetics of CYP2D6 in Ngawbe Guaymi of Panama: allele-specific PCR detection of the CYP2D6B allele and RFLP analysis.Pharmacogenetics, 3 5
T. Deguchi, M. Mashimo, T. Suzuki (1990)
Correlation between acetylator phenotypes and genotypes of polymorphic arylamine N-acetyltransferase in human liver.The Journal of biological chemistry, 265 22
F. Gonzalez, Radek Skodat, S. Kimura, M. Umeno, U. Zanger, D. Nebert, H. Gelboin, J. Hardwick, U. Meyer (1988)
Characterization of the common genetic defect in humans deficient in debrisoquine metabolismNature, 331
(1997)
SDA February
J. Wright, N. Helsby, S. Ward (1995)
The role of S-mephenytoin hydroxylase (CYP2C19) in the metabolism of the antimalarial biguanides.British journal of clinical pharmacology, 39 4
M. Kagimoto, M. Heim, Keiko Kagimotog, T. Zeugin, U. Meyer (1990)
Multiple mutations of the human cytochrome P450IID6 gene (CYP2D6) in poor metabolizers of debrisoquine. Study of the functional significance of individual mutations by expression of chimeric genes.The Journal of biological chemistry, 265 28
T. Arias, L. Jorge, E. Griese, T. Inaba, M. Eichelbaum (1993)
Polymorphic N-acetyltransferase (NAT2) in Amerindian populations of Panama and Colombia: high frequencies of point mutation 857A, as found in allele S3/M3.Pharmacogenetics, 3 6
M. Dahl, I. Johansson, L. Bertilsson, M. Ingelman-Sundberg, F. Sjöqvist (1995)
Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis.The Journal of pharmacology and experimental therapeutics, 274 1
J. Agúndez, Carmen Martínez, J. Ladero, M. Ledesma, J. Ramos, Ramón Martín, Alvaro Rodriguez, Carlos Jara, J. Benítez (1994)
Debrisoquin oxidation genotype and susceptibility to lung cancerClinical Pharmacology & Therapeutics, 55
S. Ward, F. Goto, K. Nakamura, E. Jacqz, G. Wilkinson, R. Branch (1987)
S‐mephenytoin 4‐hydroxylase is inherited as an autosomal‐recessive trait in Japanese familiesClinical Pharmacology & Therapeutics, 42
E. Skjelbo, T. Mutabingwa, I. Bygbjerg, K. Nielsen, L. Gram, K. Brøsen (1996)
Chloroguanide metabolism in relation to the efficacy in malaria prophylaxis and the S‐mephenytoin oxidation in TanzaniansClinical Pharmacology & Therapeutics, 59
A. Gough, John Miles, Nigel Spurr, J. Moss, A. Gaedigk, M. Eichelbaum, C. Wolf (1990)
Identification of the primary gene defect at the cytochrome P450 CYP2D locusNature, 347
V. Steen, O. Andreassen, A. Daly, T. Tefre, A. Børresen, J. Idle, A. Gulbrandsen (1995)
Detection of the poor metabolizer-associated CYP2D6(D) gene deletion allele by long-PCR technology.Pharmacogenetics, 5 4
Henry Lin, Chun-Ya Han, B. Lin, Steven Hardy (1994)
Ethnic distribution of slow acetylator mutations in the polymorphic N-acetyltransferase (NAT2) gene.Pharmacogenetics, 4 3
D. Bell, Jack Taylor, M. Butler, E. Stephens, J. Wiest, L. Brubaker, F. Kadlubar, G. Lucier (1993)
Genotype/phenotype discordance for human arylamine N-acetyltransferase (NAT2) reveals a new slow-acetylator allele common in African-Americans.Carcinogenesis, 14 8
J. Gut, U. Meier, T. Catin, U. Meyer (1986)
Mephenytoin-type polymorphism of drug oxidation: purification and characterization of a human liver cytochrome P-450 isozyme catalyzing microsomal mephenytoin hydroxylation.Biochimica et biophysica acta, 884 3
U. Zanger, F. Vilbois, J. Hardwick, U. Meyer (1988)
Absence of hepatic cytochrome P450bufI causes genetically deficient debrisoquine oxidation in man.Biochemistry, 27 15
G. Mikus, F. Bochner, M. Eichelbaum, P. Horák, A. Somogyi, S. Spector (1994)
Endogenous codeine and morphine in poor and extensive metabolisers of the CYP2D6 (debrisoquine/sparteine) polymorphism.The Journal of pharmacology and experimental therapeutics, 268 2
J. Jennne (1965)
Partial purification and properties of the isoniazid transacetylase in human liver. Its relationship to the acetylation of p-aminosalicylic acid.The Journal of clinical investigation, 44 12
F. Broly, D. Marez, N. Sabbagh, M. Legrand, S. Millecamps, J. Guidice, P. Boone, U. Meyer (1995)
An efficient strategy for detection of known and new mutations of the CYP2D6 gene using single strand conformation polymorphism analysis.Pharmacogenetics, 5 6
Claudine Deloménie, L. Sica, Denis Grant, Rajagopal Krishnamoorthy, J. Dupret (1996)
Genotyping of the polymorphic N-acetyltransferase (NAT2*) gene locus in two native African populations.Pharmacogenetics, 6 2
U. Zanger, H. Hauri, Jacqueline LOEPERt, JEAN-CLAUDE HOMBERGt, U. Meyer (1988)
Antibodies against human cytochrome P-450db1 in autoimmune hepatitis type II.Proceedings of the National Academy of Sciences of the United States of America, 85 21
T. Shimada, K. Misono, F. Guengerich (1986)
Human liver microsomal cytochrome P-450 mephenytoin 4-hydroxylase, a prototype of genetic polymorphism in oxidative drug metabolism. Purification and characterization of two similar forms involved in the reaction.The Journal of biological chemistry, 261 2
R. Cann (1995)
The history and geography of human genesThe Journal of Asian Studies, 54
F. Gonzalez, T. Matsunaga, K. Nagata, U. Meyer, D. Nebert, J. Pastewka, C. Kozak, J. Gillette, H. Gelboin, J. Hardwick (1987)
Debrisoquine 4-hydroxylase: characterization of a new P450 gene subfamily, regulation, chromosomal mapping, and molecular analysis of the DA rat polymorphism.DNA, 6 2
Thomas Stüven, Ernst-UIrich Griese, H. Kroemer, M. Eichelbaum, U. Zanger (1996)
Rapid detection of CYP2D6 null alleles by long distance- and multiplex-polymerase chain reaction.Pharmacogenetics, 6 5
(1979)
Defective Noxidation of sparteine in man: a new harmacogenetic defect
U. Meyer (1991)
Genotype or phenotype: the definition of a pharmacogenetic polymorphism.Pharmacogenetics, 1 2
sive metabolisers. Hum. Genet
D. Marez, M. Legrand, N. Sabbagh, J. Guidice, C. Spire, J. Lafitte, U. Meyer, F. Broly (1997)
Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: characterization of 48 mutations and 53 alleles, their frequencies and evolution.Pharmacogenetics, 7 3
Henry Lin, Chun-Ya Han, B. Lin, Steven Hardy (1993)
Slow acetylator mutations in the human polymorphic N-acetyltransferase gene in 786 Asians, blacks, Hispanics, and whites: application to metabolic epidemiology.American journal of human genetics, 52 4
Pierre Dayer, T. Kronbach, Michel Eichelbaum, U. Meyer (1987)
Enzymatic basis of the debrisoquine/sparteine-type genetic polymorphism of drug oxidation. Characterization of bufuralol 1'-hydroxylation in liver microsomes of in vivo phenotyped carriers of the genetic deficiency.Biochemical pharmacology, 36 23
K. Vatsis, W. Weber (1993)
Structural heterogeneity of Caucasian N-acetyltransferase at the NAT1 gene locus.Archives of biochemistry and biophysics, 301 1
D. Hickman, A. Risch, J. Camilleri, E. Sim (1992)
Genotyping human polymorphic arylamine N-acetyltransferase: identification of new slow allotypic variants.Pharmacogenetics, 2 5
D. Grant (1993)
Molecular genetics of the N-acetyltransferases.Pharmacogenetics, 3 1
A. Cribb, D. Grant, M. Miller, S. Spielberg (1991)
Expression of monomorphic arylamine N-acetyltransferase (NAT1) in human leukocytes.The Journal of pharmacology and experimental therapeutics, 259 3
K. Ilett, G. Chiswell, R. Spargo, Elanor Platt, Rodney Minchin (1993)
Acetylation phenotype and genotype in aboriginal leprosy patients from the north-west region of Western Australia.Pharmacogenetics, 3 5
M. Abe, T. Deguchi, T. Suzuki (1993)
The structure and characteristics of a fourth allele of polymorphic N-acetyltransferase gene found in the Japanese population.Biochemical and biophysical research communications, 191 3
J. Goldstein, M. Faletto, M. Romkes-Sparks, T. Sullivan, S. Kitareewan, J. Raucy, J. Lasker, B. Ghanayem (1994)
Evidence that CYP2C19 is the major (S)-mephenytoin 4'-hydroxylase in humans.Biochemistry, 33 7
M. Eichelbaum, A. Gross (1990)
The genetic polymorphism of debrisoquine/sparteine metabolism--clinical aspects.Pharmacology & therapeutics, 46 3
M. Eichelbaum, M. Baur, H. Dengler, B. Osikowska-Evers, G. Tieves, C. Zekorn, C. Rittner (1987)
Chromosomal assignment of human cytochrome P-450 (debrisoquine/sparteine type) to chromosome 22.British journal of clinical pharmacology, 23 4
W. Evans, M. Relling (1990)
Xbal 16- plus 9-kilobase DNA restriction fragments identify a mutant allele for debrisoquin hydroxylase: report of a family study.Molecular pharmacology, 37 5
H. Andres, R. Vogel, G. Tarr, L. Johnson, W. Weber (1987)
Purification, physicochemical, and kinetic properties of liver acetyl-CoA:arylamine N-acetyltransferase from rapid acetylator rabbits.Molecular pharmacology, 31 4
Josef Gut, T. Catin, Pierre Dayer, T. Kronbach, Ulrich Zanger, Urs Meyerll (1986)
Debrisoquine/sparteine-type polymorphism of drug oxidation. Purification and characterization of two functionally different human liver cytochrome P-450 isozymes involved in impaired hydroxylation of the prototype substrate bufuralol.The Journal of biological chemistry, 261 25
P. Evans, A. David (1994)
Genetic Factors in Drug Therapy: Clinical and Molecular Pharmacogenetics
M. Armstrong, K. Fairbrother, J. Idle, A. Daly (1994)
The cytochrome P450 CYP2D6 allelic variant CYP2D6J and related polymorphisms in a European population.Pharmacogenetics, 4 2
J. Agúndez, M. Ledesma, J. Ladero, J. Benítez (1995)
Prevalence of CYP2D6 gene duplication and its repercussion on the oxidative phenotype in a white populationClinical Pharmacology & Therapeutics, 57
N. Hanioka, Shioko Kimura, Urs Meyert, Frank Gonzalez (1990)
The human CYP2D locus associated with a common genetic defect in drug oxidation: a G1934----A base change in intron 3 of a mutant CYP2D6 allele results in an aberrant 3' splice recognition site.American journal of human genetics, 47 6
M. Romkes, M. Faletto, J. Blaisdell, J. Raucy, J. Goldstein (1991)
Cloning and expression of complementary DNAs for multiple members of the human cytochrome P450IIC subfamily.Biochemistry, 30 13
P. Vineis, H. Bartsch, N. Caporaso, A. Harrington, F. Kadlubar, M. Landi, C. Malaveille, P. Shields, P. Skipper, G. Talaska, S. Tannenbaum (1994)
Genetically based N-acetyltransferase metabolic polymorphism and low-level environmental exposure to carcinogensNature, 369
K. BrØsen, L. Gram, S. Sindrup, E. Skjelbo, K. Nielsen (1992)
PHARMACOGENETICS OF TRICYCLIC AND NOVEL ANTIDEPRESSANTS: RECENT DEVELOPMENTSClinical Neuropharmacology, 15
D. Hickman, A. Risch, V. Buckle, N. Spurr, S. Jeremiah, Angela, McCarthyt, E. Sim (1994)
Chromosomal localization of human genes for arylamine N-acetyltransferase.The Biochemical journal, 297 ( Pt 3)
F. Broly, A. Gaedigk, M. Heim, M. Eichelbaum, K. Morike, U. Meyer (1991)
Debrisoquine/sparteine hydroxylation genotype and phenotype: analysis of common mutations and alleles of CYP2D6 in a European population.DNA and cell biology, 10 8
M. Heim, U. Meyer (1990)
Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplificationThe Lancet, 336
K. Vatsis, W. Weber, D. Bell, J. Dupret, D. Evans, D. Grant, D. Hein, Henry Lin, U. Meyer, M. Relling, E. Sim, Tomokazu Suzuki, Y. Yamazoe (1995)
Nomenclature for N-acetyltransferases.Pharmacogenetics, 5 1
K. Vatsis, K. Martell, W. Weber (1991)
Diverse point mutations in the human gene for polymorphic N-acetyltransferase.Proceedings of the National Academy of Sciences of the United States of America, 88 14
M. Blum, D. Grant, W. Mcbride, M. Heim, U. Meyer (1990)
Human arylamine N-acetyltransferase genes: isolation, chromosomal localization, and functional expression.DNA and cell biology, 9 3
I. Cascorbi, N. Drakoulis, J. Brockmöller, A. Maurer, K. Sperling, I. Roots (1995)
Arylamine N-acetyltransferase (NAT2) mutations and their allelic linkage in unrelated Caucasian individuals: correlation with phenotypic activity.American journal of human genetics, 57 3
S. Wrighton, J. Stevens, G. Becker, M. Vandenbranden (1993)
Isolation and characterization of human liver cytochrome P450 2C19: correlation between 2C19 and S-mephenytoin 4'-hydroxylation.Archives of biochemistry and biophysics, 306 1
Br. J. Clin. Pharmacol
Shioko Kimura, M. Umeno, R Skoda, U. Meyer, Frank Gonzalez (1989)
The human debrisoquine 4-hydroxylase (CYP2D) locus: sequence and identification of the polymorphic CYP2D6 gene, a related gene, and a pseudogene.American journal of human genetics, 45 6
(1989)
Absent, decreased or variant P450db1 in livers with poor capacity for debrisoquine metabolism
L. Bertilsson (1995)
Geographical/Interracial Differences in Polymorphic Drug OxidationClinical Pharmacokinetics, 29
S. Morais, G. Wilkinson, J. Blaisdell, K. Nakamura, U. Meyer, J. Goldstein (1994)
The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans.The Journal of biological chemistry, 269 22
U. Meyer (1990)
Genetic polymorphisms of drug metabolism *Fundamental & Clinical Pharmacology, 4
T. Andersson, C. Reg»rdh, Y. Lou, Yuan Zhang, M. Dahl, L. Bertilsson (1992)
Polymorphic hydroxylation of S-mephenytoin and omeprazole metabolism in Caucasian and Chinese subjects.Pharmacogenetics, 2 1
(1994)
Evidence for a role for 2C19 in metabolism of S-mephenytoin in humans
E. Aklillu, I. Persson, L. Bertilsson, I. Johansson, F. Rodrigues, M. Ingelman-Sundberg (1996)
Frequent distribution of ultrarapid metabolizers of debrisoquine in an ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles.The Journal of pharmacology and experimental therapeutics, 278 1
C. Ged, D. Umbenhauer, T. Bellew, R. Bork, P. Srivastava, N. Shinriki, R. Lloyd, F. Guengerich (1988)
Characterization of cDNAs, mRNAs, and proteins related to human liver microsomal cytochrome P-450 (S)-mephenytoin 4'-hydroxylase.Biochemistry, 27 18
K. Brøsen, S. Morais, U. Meyer, J. Goldstein (1995)
A multifamily study on the relationship between CYP2C19 genotype and s-mephenytoin oxidation phenotype.Pharmacogenetics, 5 5
U. Meyer, R. Skoda, U. Zanger (1990)
The genetic polymorphism of debrisoquine/sparteine metabolism-molecular mechanisms.Pharmacology & therapeutics, 46 2
S.M.F. Demorais, H. Schweikl, J. Blaisdell, J. Goldstein (1993)
Gene structure and upstream regulatory regions of human CYP2C9 and CYP2C18.Biochemical and biophysical research communications, 194 1
M. Blum, D. Grant, A. Demierre, U. Meyer (1989)
N-acetylation pharmacogenetics: a gene deletion causes absence of arylamine N-acetyltransferase in liver of slow acetylator rabbits.Proceedings of the National Academy of Sciences of the United States of America, 86 23
Alastair Cribb, Hidefumi Nakamura, Denis Grant, Margaret Miller, S. Spielberg (1993)
Role of polymorphic and monomorphic human arylamine N-acetyltransferases in determining sulfamethoxazole metabolism.Biochemical pharmacology, 45 6
C. Masimirembwa, I. Johansson, J. Hasler, M. Ingelman-Sundberg (1993)
Genetic polymorphism of cytochrome P450 CYP2D6 in Zimbabwean population.Pharmacogenetics, 3 6
U. Meyer (1994)
The molecular basis of genetic polymorphisms of drug metabolism.The Journal of pharmacy and pharmacology, 46 Suppl 1
R. Skoda, F. Gonzalez, A. Demierre, U. Meyer (1988)
Two mutant alleles of the human cytochrome P-450db1 gene (P450C2D1) associated with genetically deficient metabolism of debrisoquine and other drugs.Proceedings of the National Academy of Sciences of the United States of America, 85 14
A. Gough, C.A.Dale Smith, Spencer Howell, C. Wolf, S. Bryant, Nigel Spurr (1993)
Localization of the CYP2D gene locus to human chromosome 22q13.1 by polymerase chain reaction, in situ hybridization, and linkage analysis.Genomics, 15 2
A. Gaedigk, M. Blum, R. Gaedigk, M. Eichelbaum, U. Meyer (1991)
Deletion of the entire cytochrome P450 CYP2D6 gene as a cause of impaired drug metabolism in poor metabolizers of the debrisoquine/sparteine polymorphism.American journal of human genetics, 48 5
P. Wedlund, W. Aslanian, E. Jacqz, C. Mcallister, R. Branch, G. Wilkinson (1985)
Phenotypic differences in mephenytoin pharmacokinetics in normal subjects.The Journal of pharmacology and experimental therapeutics, 234 3
J. Agúndez, M. Olivera, C. Martı́nez, J. Ladero, J. Benítez (1996)
Identification and prevalence study of 17 allelic variants of the human NAT2 gene in a white population.Pharmacogenetics, 6 5
David Heln, R. Ferguson, M. Doll, T. Rustan, K. Gray (1994)
Molecular genetics of human polymorphic N-acetyltransferase: enzymatic analysis of 15 recombinant wild-type, mutant, and chimeric NAT2 allozymes.Human molecular genetics, 3 5
H. Kroemer, M. Eichelbaum (1995)
"It's the genes, stupid". Molecular bases and clinical consequences of genetic cytochrome P450 2D6 polymorphism.Life sciences, 56 26
D. Grant, F. Lottspeich, U. Meyer (1989)
Evidence for two closely related isozymes of arylamine N‐acetyltransferase in human liverFEBS Letters, 244
R. Meehan, Gosden, D. Rout, N. Hastie, T. Friedberg, M. Adesnik, R. Buckland, V. Heyningen, J. Fletcher, N. Spurr (1988)
Human cytochrome P-450 PB-1: a multigene family involved in mephenytoin and steroid oxidations that maps to chromosome 10.American journal of human genetics, 42 1
D. Grant, M. Blum, M. Beer, U. Meyer (1991)
Monomorphic and polymorphic human arylamine N-acetyltransferases: a comparison of liver isozymes and expressed products of two cloned genes.Molecular pharmacology, 39 2
D. Sohn, M. Kusaka, T. Ishizaki, S. Shin, I. Jang, Jae-Gook Shin, K. Chiba (1992)
Incidence of S‐mephenytoin hydroxylation deficiency in a Korean population and the interphenotypic differences in diazepam pharmacokineticsClinical Pharmacology & Therapeutics, 52
E. Sim, D. Hickman, E. Coroneos, S. Kelly (1992)
Arylamine N-acetyltransferase.Biochemical Society transactions, 20 2
T. Inaba, M. Jurima, W. Kalow (1986)
Family studies of mephenytoin hydroxylation deficiency.American journal of human genetics, 38 5
U. Meier, P. Dayer, P. Male, T. Kronbach, U. Meyer (1985)
Mephenytoin hydroxylation polymorphism: Characterization of the enzymatic deficiency in liver microsomes of poor metabolizers phenotyped in vivoClinical Pharmacology & Therapeutics, 38
A. Küpfer, R. Patwardhan, S. Ward, S. Schenker, R. Preisig, R. Branch (1984)
Stereoselective metabolism and pharmacogenetic control of 5-phenyl-5-ethylhydantoin (nirvanol) in humans.The Journal of pharmacology and experimental therapeutics, 230 1
Jean-Marie Dupretl, Denis Grants (1992)
Site-directed mutagenesis of recombinant human arylamine N-acetyltransferase expressed in Escherichia coli. Evidence for direct involvement of Cys68 in the catalytic mechanism of polymorphic human NAT2.The Journal of biological chemistry, 267 11
D. Grant, K. Morike, M. Eichelbaum, U. Meyer (1990)
Acetylation pharmacogenetics. The slow acetylator phenotype is caused by decreased or absent arylamine N-acetyltransferase in human liver.The Journal of clinical investigation, 85 3
M. Dahl, Q. Yue, H. Roh, I. Johansson, J. Sawe, F. Sjôqvist, L. Bertilsson (1995)
Genetic analysis of the CYP2D locus in relation to debrisoquine hydroxylation capacity in Korean, Japanese and Chinese subjects.Pharmacogenetics, 5 3
I. Johansson, Eva Lundqvist, L. Bertilsson, M. Dahl, F. Sjöqvist, M. Ingelman-Sundberg (1993)
Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine.Proceedings of the National Academy of Sciences of the United States of America, 90 24
Rachel Tyndale, T. Aoyama, Franck Broly, Tamihide Matsunaga, Tadanobu Inaba, Werner Kalow, H. Gelboin, U. Meyer, Frank Gonzalez (1991)
Identification of a new variant CYP2D6 allele lacking the codon encoding Lys-281: possible association with the poor metabolizer phenotype.Pharmacogenetics, 1 1
(1994)
Human N-acetyltransferases. In Conjugation-Deconjugation. Reactions in Drug Metabolism and Toxicity
D. Marez, N. Sabbagh, M. Legrand, J. Lo-Guidice, P. Boone, F. Broly (1995)
A novel CYP2D6 allele with an abolished splice recognition site associated with the poor metabolizer phenotype.Pharmacogenetics, 5 5
Ingolf Cascorbi, Jürgen Brockmöller, Steffen Bauer, Torsten Reum, Ivar Roots (1996)
NAT2*12A (803A-->G) codes for rapid arylamine n-acetylation in humans.Pharmacogenetics, 6 3
J. Goldstein, S. Morais (1994)
Biochemistry and molecular biology of the human CYP2C subfamily.Pharmacogenetics, 4 6
L. Distlerath, P. Reilly, M. Martín, G. Davis, G. Wilkinson, F. Guengerich (1985)
Purification and characterization of the human liver cytochromes P-450 involved in debrisoquine 4-hydroxylation and phenacetin O-deethylation, two prototypes for genetic polymorphism in oxidative drug metabolism.The Journal of biological chemistry, 260 15
S. Ohsako, T. Deguchi (1990)
Cloning and expression of cDNAs for polymorphic and monomorphic arylamine N-acetyltransferases from human liver.The Journal of biological chemistry, 265 8
A. Mahgoub, L. Dring, J. Idle, R. Lancaster, R.L Smith (1977)
POLYMORPHIC HYDROXYLATION OF DEBRISOQUINE IN MANThe Lancet, 310
W. Weber (1987)
The acetylator genes and drug response
Su-lan Wang, Jin‐ding Huang, M. Lai, Biing-Hui Liu, M. Lai (1993)
Molecular basis of genetic variation in debrisoquin hydroxylation in Chinese subjects: Polymorphism in RFLP and DNA sequence of CYP2D6Clinical Pharmacology & Therapeutics, 53
U. Meiert, Urs, Meyer (1987)
Genetic polymorphism of human cytochrome P-450 (S)-mephenytoin 4-hydroxylase. Studies with human autoantibodies suggest a functionally altered cytochrome P-450 isozyme as cause of the genetic deficiency.Biochemistry, 26 25
L. Bertilsson, M. Dahl, F. Sjöqvist, A. Åberg‐Wistedt, M. Humble, I. Johansson, Eva Lundqvist, M. Ingelman-Sundberg (1993)
Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquineThe Lancet, 341
I. Johansson, M. Oscarson, Q. Yue, L. Bertilsson, F. Sjöqvist, M. Ingelman-Sundberg (1994)
Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation.Molecular pharmacology, 46 3
F. Broly, Meyer Ua (1993)
Debrisoquine oxidation polymorphism: phenotypic consequences of a 3-base-pair deletion in exon 5 of the CYP2D6 gene.Pharmacogenetics, 3 3
H. Yokota, S. Tamura, H. Furuya, S. Kimura, M. Watanabe, I. Kanazawa, I. Kondo, F. Gonzalez (1993)
Evidence for a new variant CYP2D6 allele CYP2D6J in a Japanese population associated with lower in vivo rates of sparteine metabolism.Pharmacogenetics, 3 5
A. Ward, D. Hickman, J. Gordon, E. Sim (1992)
Arylamine N-acetyltransferase in human red blood cells.Biochemical pharmacology, 44 6
(1992)
Drugs in special patient groups: clinical importance of genetics in drug effects
P. Wolkenstein, V. Carrière, D. Charue, S. Bastuji‐Garin, J. Revuz, J. Roujeau, P. Beaune, M. Bagot (1995)
A slow acetylator genotype is a risk factor for sulphonamide-induced toxic epidermal necrolysis and Stevens-Johnson syndrome.Pharmacogenetics, 5 4
F. Gonzalez, Francis Vilbois, James Hardwick, O. McBride, D. Nebert, H. Gelboin, U. Meyer (1988)
Human debrisoquine 4-hydroxylase (P450IID1): cDNA and deduced amino acid sequence and assignment of the CYP2D locus to chromosome 22.Genomics, 2 2
M. Heim, U. Meyer (1992)
Evolution of a highly polymorphic human cytochrome P450 gene cluster: CYP2D6.Genomics, 14 1
T. Ebisawa, T. Deguchi (1991)
Structure and restriction fragment length polymorphism of genes for human liver arylamine N-acetyltransferases.Biochemical and biophysical research communications, 177 3
R. Ferguson, M. Doll, T. Rustan, K. Gray, D. Hein (1994)
Cloning, expression, and functional characterization of two mutant (NAT2(191) and NAT2(341/803)) and wild-type human polymorphic N-acetyltransferase (NAT2) alleles.Drug metabolism and disposition: the biological fate of chemicals, 22 3
J. Richman (1987)
Medicine and Health
S. Morais, G. Wilkinson, J. Blaisdell, U. Meyer, K. Nakamura, J. Goldstein (1994)
Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese.Molecular pharmacology, 46 4
R. Hayes, Wenfang Bi, N. Rothman, F. Broly, N. Caporaso, Peiwen Feng, Xiejun You, S. Yin, R. Woosley, U. Meyer (1993)
N-acetylation phenotype and genotype and risk of bladder cancer in benzidine-exposed workers.Carcinogenesis, 14 4
▪ Abstract One of the major causes of interindividual variation of drug effects is genetic variation of drug metabolism. Genetic polymorphisms of drug-metabolizing enzymes give rise to distinct subgroups in the population that differ in their ability to perform certain drug biotransformation reactions. Polymorphisms are generated by mutations in the genes for these enzymes, which cause decreased, increased, or absent enzyme expression or activity by multiple molecular mechanisms. Moreover, the variant alleles exist in the population at relatively high frequency. Genetic polymorphisms have been described for most drug metabolizing enzymes. The molecular mechanisms of three polymorphisms are reviewed here. The acetylation polymorphism concerns the metabolism of a variety of arylamine and hydrazine drugs, as well as carcinogens by the cytosolic N-acetyltransferase NAT2. Seven mutations of the NAT2 gene that occur singly or in combination define numerous alleles associated with decreased function. The debrisoquine-sparteine polymorphism of drug oxidation affects the metabolism of more than 40 drugs. The poor metabolizer phenotype is caused by several “loss of function” alleles of the cytochrome P450 CYP2D6 gene. On the other hand, “ultrarapid” metabolizers are caused by duplication or amplification of an active CYP2D6 gene. Intermediate metabolizers are often heterozygotes or carry alleles with mutations that decrease enzyme activity only moderately. The mephenytoin polymorphism affects the metabolism of mephenytoin and several other drugs. Two mutant alleles of CYP2C19 have so far been identified to cause this polymorphism. These polymorphisms show recessive transmission of the poor or slow metabolizer phenotype, i.e. two mutant alleles define the genotype in these individuals. Simple DNA tests based on the primary mutations have been developed to predict the phenotype. Analysis of allele frequencies in different populations revealed major differences, thereby tracing the molecular history and evolution of these polymorphisms.
Annual Review of Pharmacology and Toxicology – Annual Reviews
Published: Apr 1, 1997
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.